AzTrials
AzTrials

Ovarian CancerPhase 2NCT07355010

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

A Phase 2 study testing fuzuloparib, Famitinib and SHR-1701 in people with Ovarian Cancer, run by Qinglei Gao.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

This study is a randomized, open-label, double-cohort, national multi-center clinical research. The aim is to evaluate the newly diagnosed FIGO 2014 stage III-IV pathology of neoadjuvant therapy with fluzoparib combined with famitinib or fluzoparib combined with SHR-1701, based on the Fagotti laparoscopy score or… Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Ovarian Cancer
What is being tested?
fuzuloparib, Famitinib and SHR-1701
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
104 participants
Where
No sites listed yet
Study dates
30 Dec 2025to 30 Dec 2030
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The subjects voluntarily joined this study and signed the informed consent form;
  • Age ≥18 years old (calculated from the date of signing the informed consent);
  • Newly diagnosed high-grade (or moderately and poorly differentiated) serous ovarian cancer, fallopian tube cancer or primary peritoneal cancer in pathology; Ovarian endometrioid adenocarcinoma of grade ≥ II; Mixed tumor: High-grade serous type or ≥ grade II endometrioid components must be present.
  • FIGO 2014 Phase III-IV;
  • The subjects have at least one measurable lesion that can be evaluated by CT or MRI (RECIST v1.1) ;
  • After assessment by the researcher, R0 resection cannot be achieved or the surgery cannot be tolerated;
Show all 23Show fewer
  • The criteria for judging that <s:1> cannot reach R0 resection include:
  • Fagotti endoscopic score ≥8 points;
  • When laparoscopic assessment methods are difficult to implement, an upper abdominal Suidan's CT score of ≥3 points can be adopted.
  • The criteria for the inability to tolerate surgery may be considered:
  • Body Mass Index: BMI≥40;
  • Multiple chronic diseases;
  • Malnutrition or hypoproteinemia;
  • Moderate to massive ascites;
  • Newly diagnosed venous thromboembolism;
  • Physical condition: ECOG PS \&gt; 2;
  • Other reasons as determined by the researcher;
  • ECOG PS: 0-2;
  • The subject has been tested and confirmed by a professional institution to be of the wild type of germline BRCA1/2.
  • The functions of vital organs meet the following requirements (no blood components or cell growth factors are allowed to be used within 14 days before the first administration) :
  • <s:1> Absolute neutrophil count ≥1.5×109/L; <s:1> platelet count ≥100×109/L; <s:1> hemoglobin ≥9 g/dL; Serum albumin ≥3g/dL; Bilirubin ≤1.5 times ULN; <s:1> ALT and AST ≤2.5 times ULN, and ≤5 times ULN in the presence of liver metastasis; Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (calculated according to the Cockcroft-Gault formula);
  • Fertile subjects must undergo a blood pregnancy test with a negative result within one week before the first administration of the drug, and must not be in the lactation period. They must agree to take effective contraceptive measures during the trial period and for six months after the last administration of the trial drug. If there is any suspected or confirmed pregnancy, they must immediately notify the investigator.
  • The subjects were willing to cooperate in completing the questionnaire survey on quality of life during the trial treatment and follow-up, and agreed that the results of the questionnaire survey could be used for clinical research.

Who cannot join

  • In the past (within 5 years) or concurrently with other uncured malignant tumors, for cured thyroid cancer, basal cell carcinoma of the skin, carcinoma in situ, and those who have completed radical mastectomy \&gt; Breast cancer that has not recurred for three years is excluded.
  • The subjects have untreated central nervous system metastases Patients who have previously received systemic or radical treatment for brain or meningeal metastases (radiotherapy or surgery), and whose stability has been maintained for at least one month as confirmed by imaging, and who have stopped systemic hormone therapy (10mg/ day prednisone or other equivalent therapeutic hormones) for more than two weeks and have no clinical symptoms, can be included.
  • The subjects have previously received treatment with known or possible PARP inhibitors, anti-angiogenic drugs, and PD-L1/TGF-β.
  • Those who are unable to swallow tablets normally or have abnormal gastrointestinal function, which the researcher determines may affect drug absorption;
  • Those who have experienced intestinal obstruction or gastrointestinal perforation in the recent period (within 3 months);
  • There are poorly controlled clinical symptoms or diseases of the heart, such as: (1) NYHA grade 2 or above heart failure; (2) unstable angina pectoris; (3) Myocardial infarction occurred within one year; (4) clinically significant supventricular or ventricular arrhythmias requiring treatment or intervention; (5) QTc\&gt; 470ms;
Show all 18Show fewer
  • If any severe bleeding event with a grade of 2 or above in CTCAE 5.0 occurs within 4 weeks before the first medication, such as gastrointestinal bleeding, hemorrhagic gastric ulcer or phlebitis, etc., and the fecal occult blood is positive during the baseline period, a re-examination can be conducted. If the re-examination is still positive, a gastroscopy or colonoscopy should be performed in combination with clinical judgment when necessary.
  • The subject has received platelet or red blood cell transfusion within 14 days before the start of treatment;
  • Accompanied by active ulcers, unhealed wounds or fractures;
  • The subjects had active infections or developed unexplained fever during the screening period or before the first administration. 38.5 degrees
  • The subject has congenital or acquired immune deficiency (such as HIV infection), or active hepatitis (Hepatitis B reference: HBsAg positive and HBV DNA≥500 IU/ml or 1000 copies/mL; Hepatitis C reference: HCV antibody positive and HCV RNA \&gt; upper limit of normal value);
  • Those who had previously received radiotherapy, chemotherapy, hormone therapy, or molecular targeted therapy and had less than 4 weeks before the completion of the treatment (the last medication) (for oral molecular targeted drugs, it was less than 5 drug half-lives); Adverse events caused by previous treatment (excluding alopecia) have not recovered to grade ≤1 (CTCAE 5.0);
  • Within 6 months prior to the first medication, there have been events of grade ≥3 arterial thrombosis or venous thrombosis, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.
  • Those with a history of hereditary or acquired bleeding or coagulation disorders (such as hemophilia patients, coagulation disorders, thrombocytopenia, etc.);
  • During the study period, the subjects may receive other systemic anti-tumor treatments;
  • Those with hypertension who have not achieved good control through antihypertensive drug treatment (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);
  • The subjects are pregnant, breastfeeding or plan to become pregnant during the study treatment period;
  • As determined by the researchers, the subjects have other factors that may lead to the forced termination of this study, such as other serious diseases (including mental illness) requiring combined treatment, severe laboratory test abnormalities, accompanied by family or social factors that may affect the safety of the subjects, or the collection of data and samples.

About this study

This study is a randomized, open-label, double-cohort, national multi-center clinical research. The aim is to evaluate the newly diagnosed FIGO 2014 stage III-IV pathology of neoadjuvant therapy with fluzoparib combined with famitinib or fluzoparib combined with SHR-1701, based on the Fagotti laparoscopy score or upper abdominal Suidan's by the researchers The CT score assesses the efficacy and safety of patients with germline BRCA wild-type ovarian cancer who cannot achieve R0 resection or cannot tolerate initial cytoreductive surgery, as well as the efficacy and safety of surgery, adjuvant therapy, and combined maintenance treatment regimens based on fluzoparib.

The primary endpoint was the objective response rate (ORR) after neoadjuvant therapy as assessed by the researchers based on the RECIST v1.1 criteria. Meanwhile, the chemotherapy response score (CRS), event-free survival (EFS), disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) were also examined. The safety, tolerability and patient-reported outcomes (EQ-5D-5L) of the two cohorts were investigated.

A total of 104 newly diagnosed epithelial ovarian cancer patients with germline BRCA wild-type (FIGO 2014 stage III-IV) are planned to be enrolled.

Conditions
Ovarian Cancer
Being tested
fuzuloparib, Famitinib, SHR-1701
Medical subject headings
Ovarian Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • fuzuloparibDrug

    fuzuloparib 150mg bid PO

  • FamitinibDrug

    famitinib 10mg qd PO

  • SHR-1701Drug

    SHR-1701 1800 mg IV Q3W

Study groups in NCT07355010
Study groupRoleWhat they receive
Fuzuloparib and FamitinibExperimentalfuzuloparib and famitinib
Receives: Drug: fuzuloparib; Drug: Famitinib
Fuzuloparib and SHR-1701Experimentalfuzuloparib and SHR-1701
Receives: Drug: fuzuloparib; Drug: SHR-1701

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. objective response rate，ORR

    Measured: From enrollment to the end of neoadjuvant treatment at around 8 weeks"

Secondary outcomes (3)

  1. event free survival

    Measured: It is defined as the time from the start of randomization to the first occurrence of any of the following events (disease progression beyond surgical treatment, local or distant recurrence, death of any cause), whichever occurs first, up to 5 years.

  2. disease free survival

    Measured: It is defined as the period from the first study medication in the adjuvant therapy stage after cytoreductive surgery to disease recurrence or death due to any cause (whichever occurs first), up to 5 years.

  3. progression free survival

    Measured: It is defined as the period from the start of the first study medication in the maintenance treatment stage to tumor progression or death for any reason (whichever occurs first), up to 5 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2026
  2. Study start30 Dec 2025 (estimated)
  3. Primary completion30 Dec 2028 (estimated)
  4. Study completion30 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
104 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07355010
Sponsor's protocol ID
MA-OC-II-016
Status last verified
Jan 2026
First submitted
16 Nov 2025
Last updated
21 Jan 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing fuzuloparib, Famitinib and SHR-1701 in people with Ovarian Cancer, run by Qinglei Gao.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

objective response rate，ORR (time frame: From enrollment to the end of neoadjuvant treatment at around 8 weeks"). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07355010.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in